Results 81 to 90 of about 462,118 (243)

Methotrexate-Induced Mucositis: A Consequence of Medication Error in a Rheumatoid Arthritis Patient. [PDF]

Cureus, 2023
Shrestha R, Ojha SK, Jha SK, Jasraj R, Fauzdar A.   +4 more
europepmc   +1 more source

Assessment of Nurses’ Perceived Barriers and Behaviors to Reporting Medication Errors in Hospitals of Lorestan University of Medical Sciences, Iran [PDF]

Background: Medication errors are the most common medical errors and are one of the major challenges threatening the health system. This study aimed to determine nurses’ perceived barriers and behaviors to reporting medication errors in 2011. Methods:
حیدری, حشمت اله, پیرزاده, آسیه, کامران, عزیز   +2 more
core  

Families, nurses and organisations contributing factors to medication administration error in paediatrics: a literature review [PDF]

, 2015
Background: Medication error is the most common adverse event for hospitalised children and can lead to significant harm. Despite decades of research and implementation of a number of initiatives, the error rates continue to rise, particularly those ...
Alomari, A, Davidson, PM, Lewis, J, Wilson, V   +3 more
core   +2 more sources

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

A text mining approach to categorize patient safety event reports by medication error type. [PDF]

Sci Rep, 2023
Boxley C, Fujimoto M, Ratwani RM, Fong A.   +3 more
europepmc   +1 more source

Prescribing errors : what’s the story? [PDF]

, 2001
Although prescribing errors are one of the most common causes of preventable iatrogenic injury, there have been relatively few studies of their incidence and causes. The majority of the studies that have been carried out have been based in secondary care.
Dean, Bryony
core  

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Interventions to Minimize Medication Error by Nurses in Intensive Care: A Scoping Review Protocol. [PDF]

Nurs Rep, 2023
Coelho F, Furtado L, Mendonça N, Soares H, Duarte H, Costeira C, Santos C, Sousa JP.   +7 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source